Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the chief financial officer now directly owns 150,900 shares in the company, valued at $647,361. The trade was a 7.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Daron Evans also recently made the following trade(s):
- On Thursday, December 12th, Daron Evans bought 9,000 shares of Rezolute stock. The stock was purchased at an average price of $4.60 per share, for a total transaction of $41,400.00.
Rezolute Stock Performance
Shares of Rezolute stock opened at $4.08 on Thursday. The firm has a market cap of $236.41 million, a PE ratio of -3.21 and a beta of 1.01. The business's 50 day simple moving average is $5.14 and its 200 day simple moving average is $4.78. Rezolute, Inc. has a 52-week low of $0.86 and a 52-week high of $6.19.
Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). As a group, equities research analysts predict that Rezolute, Inc. will post -0.99 EPS for the current year.
Analyst Ratings Changes
Most People Are Dead Wrong.
From Brownstone Research | Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence.
Everyone's talking about AI right now.
But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.
Several brokerages have recently issued reports on RZLT. Wedbush reissued an "outperform" rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They issued a "buy" rating and a $11.00 target price for the company. BTIG Research increased their price target on Rezolute from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, September 10th. JMP Securities reiterated a "market outperform" rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of Rezolute in a research note on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Rezolute currently has a consensus rating of "Buy" and an average price target of $24.13.
Get Our Latest Stock Analysis on RZLT
Institutional Investors Weigh In On Rezolute
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jeppson Wealth Management LLC acquired a new position in shares of Rezolute during the 2nd quarter worth about $45,000. MML Investors Services LLC acquired a new stake in shares of Rezolute in the third quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute during the third quarter worth about $65,000. Virtu Financial LLC boosted its position in Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock valued at $126,000 after purchasing an additional 9,551 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company's stock valued at $145,000 after purchasing an additional 22,660 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.
Rezolute Company Profile
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
